TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Peak Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Symptom Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time to symptomatic flare
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with Best Practice Guidelines (BPGs)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in composite intima-media thickness (IMT) in the carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ventilator-Induced Lung Injury (VILI) measured by Serum Cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gradation of uveitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Change From Baseline in Total Dysmenorrheal Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infrared temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discrepancy in distance between palpation vs. ultrasound midpoint of L4/5 interspace
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence Based on AUC(0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence Based on AUC(0-∞)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioequivalence Based on Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Suicide Risk Screening
Endpoint domain: Adverse events/effects
Primary endpoint: Suicide Risk Detection
Endpoint domain: Adverse events/effects
Primary endpoint: Safety Planning & Suicide Composite
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in actinic keratosis count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cognitive functions performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Occurrence of dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Occurrence of Grade 3 and 4 abnormalities in safety-related laboratory parameters
Endpoint domain: Adverse events/effects
Primary endpoint: MS relapses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Flow mediated Dilation (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Depth of Sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of fecal calprotectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Immunized Infants Exposed to High Breast Milk Anti-rotavirus Immunoglobulin-A Who Fail to Seroconvert
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Immunized Infants Exposed to Transplacentally-acquired, Rotavirus-specific, Infant Serum IgG Who Fail to Sero-convert
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of Immunized Infants Exposed to Maternal HIV Infection Who Fail to Seroconvert
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With an Overall Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percent improvement Maximum inspiratory pressure (MIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: percent improvement Maximum expiratory pressure (MEP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in the Beck Depression Inventory Total Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Increase in overall bone health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Return to work/major activities
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Excellent CPR achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression Free Survival at 6 months (PFS-6)
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of patients with severe toxicity within 6 months from randomization
Endpoint domain: Adverse events/effects
Primary endpoint: Heart Rate Variability - SDNN
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Heart Rate Variability - RMSSD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: PIVC failure
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of treatment emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and magnitude of treatment emergent clinical laboratory abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative Packed Red Blood Cell (PRBC) Volume in the Drainage Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percent Change in Circulating Osteoprogenitor Cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With Serious Adverse Events (SAEs) and Non-SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Participant Comfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate of dose-limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change of glycated hemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: scleroderma ulcer healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative rescue analgesia consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: PASI-75 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Pain rating during childbirth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility and safety of transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eliciting dose thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain activity in the emotional and cognitive core regions of the brain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hospitalization for COVID-19 deterioration or death
Endpoint domain: Mortality/survival
Primary endpoint: Autonomy evolution
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Inter-scan variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of Strep throat infections
Endpoint domain: Adverse events/effects
Primary endpoint: Postoperative recovery of bowel function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Geometric mean suppression of proliferation marker Ki67
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion rate of iRBD to neurodegenerative diseases
Endpoint domain: Mortality/survival
Primary endpoint: Average Daily Pain Intensity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline-to-follow up changes in inter-HD weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Breastfeeding status
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Score on Sensory Subscale of Quality of Life Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Score on Motor Subscale of Quality of Life Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Insertion-, localization- and removal-related events
Endpoint domain: Adverse events/effects
Primary endpoint: Change of CD8+ tumor infiltrating lymphocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in tracheal interleukin 6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Blood Flow to the proximal femur
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reversion of vaginal atrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Microscopic lesions in the upper digestive tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of unprotected sex acts
Endpoint domain: Adverse events/effects
Primary endpoint: Word List Memory Total - ADAS-cog
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Occurrence of perinatal death
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of IUGR defined as birth weight below the 10th percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HR-HPV clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: serum biomarker concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression of disease severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Hot Flash Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hot Flash Related Daily Interference Scale (HFRDIS)
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Number of participants who log in at least 10 times and open at least 3 coping skills exercises
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Mean score on app usability questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of aspirin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical outcome of direct hip approach
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma symptoms control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Health outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Risk of Hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percent of Eosinophils in the Bronchoalveolar Lavage Fluid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of days with moderate hyperoxia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of hematological engraftment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Safety of the administration of autologous haematopoietic stem cells transduced with LV-GLOBE
Endpoint domain: Adverse events/effects
Primary endpoint: Failure of Bakri Balloon
Endpoint domain: Adverse events/effects
Primary endpoint: Arithmetic Mean of Individual Sun Protection Factor (SPFi) Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Montgomery Asberg Depression Rating Scale (MADRS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: hs-C reactive protein (hs-CRP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in gingivitis levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Mass Index (BMI)-for-age percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maternal methylation of μ-opioid receptor (OPRM1) gene
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: COVID 19 infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in time spent awake during the night
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Frequency and magnitude of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: gametocyte prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants with 99mTc-anti-TNF-alpha joint and skin uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Irritability as measured by the Aberrant Behavior Checklist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Home situations as measured by the Home Situations Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Proportion of children with serotype-specific IgG concentration >= 0.35ug/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of children with OPA >=1:8 titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Treatment toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants Achieving Hemostasis Within 4 Minutes After Treatment Start
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence/absence of Velopharyngeal Insufficiency (VPI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of days gambled per month
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Change in Unified Wilson's Disease Rating Scale (UWDRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the ulcer area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in complete ulcer healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Birth admission length of stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Single muscle fiber contractile function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mitochondrial content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Post-intensive care syndrome (PICS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: HSQ 12 score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Strength of quadriceps (0-5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero extrapolated to infinite time [AUC(INF)] of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve from time zero to the time of the last quantifiable concentration [AUC(0-T)] of rosuvastatin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Major Cardiac Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in serum FGF-23 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of bortezomib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neurocognitive changes detected through Moca Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes of Autonomy in daily activities detected through the Barthel Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in quality of life detected though the EORTC QLQ-C15-PAL questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: number of patients with a VAS scale more than 40
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: maximally tolerated dose (MTD)
Endpoint domain: Adverse events/effects
Primary endpoint: toxicity of the regimen
Endpoint domain: Adverse events/effects
Primary endpoint: Time to discharge after surgery
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Objective Intracranial Response (OIRR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in WOMAC pain subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Time to first subsequent treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in Visual Analogue Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in clinical signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute Change in Percent Predicted Forced Expiratory Volume in 1 Second (ppFEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in The Knee injury and Osteoarthritis Outcome Score (KOOS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the International Knee Documentation Committee 2000 (IKDC 2000) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the quality of life score (EQ- 5D- 5L)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in functional status according to The Timed Up and Go Test (TUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Associative Memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Total duration of NIV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: initiation of HIV care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: retention in HIV care
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: improved HIV health outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum-tolerated dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of asthma hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Vaccination reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Provider Delivery Service Practices
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants With HIV-1 RNA ≥ 50 Copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Participants Achieving LDL-C Treatment Goal After 6-week Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants Achieving LDL-C Treatment Goal After 12-week Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants with severe coronary artery calcification
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correlation between 24h ambulatory central blood pressure and target-organ damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of Participants With an IGA Score of 'Clear' or 'Almost Clear'
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plaque index (PI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Bleeding index (BI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Gingival index (GI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Oral health outcomes
Primary endpoint: Erythemal Scoring Scale (ESS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Plaque Inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gastrointestinal perforation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Measure of [14C] CR845 and total radioactivity in plasma, urine, feces, and dialysate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Extent of recovery of [14C] CR845 and radioactivity related to [14C] CR845
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative amount of [14C] CR845 and [14C] CR845-equivalents in urine and feces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effectiveness of the NatroxTM Topical Oxygen Device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trans epidermal water loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Standing and Supine Systolic and Diastolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time course of body temperature (fever)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Viral load over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Symptom scores of throat clearing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptom scores of globus sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes